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ABSTRACT 
Background: Human papil lomavirus (HPV) vaccinat ion programs were f irst  implemented in 2007. We 
conducted a systemat ic review and meta-analysis to examine the populat ion-level impact  and herd effect s 
following female HPV vaccinat ion programs, to verify whether the high eff icacy measured in randomized 
cont rolled clinical t rials are materialising under real-world condit ions. 
 
Methods: We searched Medline and Embase databases (01/ 2007-02/ 2014), and conference abst racts for t ime-
t rend studies examining changes, between the pre- and post -vaccinat ion periods, in the incidence/ prevalence 
of at  least  one HPV-related endpoint : HPV infect ion, anogenital warts (AGW), and high-grade cervical lesions. 
We derived pooled relat ive risk (RR) est imates using random effect  models. We st rat if ied all analyses by age 
and gender. We performed subgroups analysis by comparing studies according to vaccine type, vaccinat ion 
coverage and years since vaccinat ion implementat ion. We assessed heterogeneit y across studies using I2 and 
F2 stat ist ics. We performed t rends analysis to examine dose-response between HPV vaccinat ion coverage and 
each study effect  measure. 
 
Findings: We ident if ied 20 eligible studies, conducted in nine high-income count ries, and represent ing >140 
million person-years of follow-XS,QFRXQWULHVZLWKIHPDOHYDFFLQDWLRQFRYHUDJH+39-16/ 18 infect ions 
and AGW decreased signif icant ly between the pre- and post -vaccinat ion periods by 68% (RR=0·32, 
95%CI[0·19;0·52]) and 61% (RR=0·39, 95%CI[0·22;0·71]), respect ively,  among females <20 years. Signif icant  
reduct ions in HPV-31/ 33/ 45 among females <20 years (RR=0·72, 95%CI[0·54;0·96]), and AGW among males <20 
years (RR=0·66, 95%CI[0·47;0·91]) and older females (RR=0·68, 95CI[0·51;0·89]) were also observed, 
respect ively suggest ing cross-protect ion and herd effects. In count ries with female vaccinat ion coverage 
<50%, signif icant  reduct ions were observed for HPV-16/ 18 infect ion (RR=0·50, 95%CI[0·34;0·74]) and AGW 
(RR=0·86, 95%CI[0·79;0·94]) among females <20 years, with no indicat ion of cross-protect ion or herd effect s. 
 
Interpretation: Our results are promising for the long-term populat ion-level impact  of HPV vaccinat ion 
programs. However, cont inued monitoring is essent ial to ident ify any signals of potent ial waning eff icacy or 
type-replacement .  
 
Funding: The Canadian Inst itutes of Health Research  
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INTRODUCTION 
Since 2007, 52 out  of 195 count ries have implemented human papil lomavirus (HPV) vaccinat ion programs (41% 
of High Income (HIC) and 15% of Low and Middle Income Count ries (LMIC)1-4). The populat ion-level impact  of 
HPV vaccinat ion programs is expected to vary substant ially between these count ries dependant  on vaccine 
used, implementat ion st rategies and vaccinat ion coverage achieved. Two HPV vaccines are current ly available 
worldwide: the bivalent  vaccine, which targets HPV t ypes 16 and 18 (associated with 70-80% of cervical 
cancers globally5), and the quadrivalent  vaccine, which addit ionally targets HPV types 6 and 11 (associated 
with 85-95% of anogenital warts (AGW) cases6). Most  HIC are current ly using the quadrivalent  vaccine, whilst  
the picture is mixed for LMIC.2,7 Alt hough all HPV vaccinat ion programs target  pre-adolescent  girls (including 
or not  catch-up programs for older females), a few count ries, such as the United States (U.S.) and Aust ralia, 
have recent ly included boys.8,9 Finally, in HIC, vaccinat ion coverage among the younger cohorts of females 
ranges from nearly 90% to less than 50% depending most ly on whether the count ries have school- or non-
school based programs, respect ively.10  
 
Large internat ional randomized cont rolled clinical t rials have shown both HPV vaccines to be safe and well-
tolerated, to be highly eff icacious against  vaccine-type persistent  HPV infect ion and precancerous cervical 
lesions among women (Vaccine eff icacy = 93%-100%),11,12 and to provide some degree of cross-protect ion 
against  three non-vaccine types (HPV-31/ 33/ 45),12-14 associated with 10-15% of cervical cancers worldwide.15 
Current  evidence from clinical t rials also suggests that  cross-protect ive vaccine eff icacy est imates against  
infect ions and lesions associated with HPV-31/ 33/ 45 are higher for t he bivalent  vaccine than the 
quadrivalent .16 Following clinical t rials, mathemat ical models have been used to predict  the long-term 
populat ion-level effect iveness and cost -effect iveness of vaccinat ion programs delivered in dif ferent  set t ings. 
Modeling studies have consistent ly predicted that  the overall burden of HPV-related diseases amongst  females 
will substant ially decline within the next  decades through vaccinat ion, and that  vaccinat ing girls against  HPV 
is highly cost -effect ive in most  count ries.17-19 Despite consistency in model predict ions of the direct  impact  of 
HPV vaccinat ion among vaccinated girls, uncertainty remains about  t he potent ial populat ion-level impact  of 
cross-protect ion and herd protect ion (e.g., indirect  impact  of vaccinat ing girls on HPV in unvaccinated males 
and older females), and the vaccinat ion coverage necessary to achieve substant ial herd effects.  20-24 This 
informat ion is crucial to help guide vaccine choices and inform decisions about  vaccinat ion of males.  
 
Now that  more than seven years have elapsed since the implementat ion of the f irst  HPV vaccinat ion programs 
in 2007 (Appendix-Table S1), it  is t imely to verify whether the promising results f rom clinical t rials and model 
proj ect ions are materialising at  the populat ion-level.  An increasing number of post -vaccinat ion surveillance 
studies have recent ly been published using several intermediate endpoints (e.g.,  HPV infect ion, AGW, and 
precancerous cervical lesions).  The obj ect ive of this systemat ic review and meta-analysis is to summarize 
current  evidence on the populat ion-level impact  of HPV vaccinat ion, as measured in t ime-t rend studies among 
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females targeted for vaccinat ion, and among males and older females. We focussed on the following HPV-
related endpoints: 1) HPV infect ion; 2) AGW; and 3) high-grade cervical lesions.  
 
METHODS 
Search st rategy and select ion criteria  
We systemat ically reviewed the worldwide literature and report  it  in accordance with the PRISMA guidelines.25 
Studies were eligible if  they fulf il led the following criteria: 1) they provided data on at  least  one of the 
following endpoints: HPV infect ion, AGW, histopathologically conf irmed high-grade cervical lesions (CIN 2 or 
worse); 2) t he populat ion-level impact  was assessed by comparing the f requency (prevalence or incidence) of 
the endpoint  between the pre- and post -vaccinat ion periods (t ime-t rend studies); 3) data from the pre- and 
post -vaccinat ion periods were collected among the same populat ion sources and using the same recruitment  
methodology.  
 
We excluded studies with t he following characterist ics because they did not  measure populat ion-level impact : 
1) HPV vaccinat ion was administered as part  of an individual-based randomized t rial; or 2) HPV vaccinat ion 
impact  was assessed by comparing the frequency of t he endpoint  between vaccinated and unvaccinated 
individuals during the post -vaccinat ion period.  
 
Our search st rategy involved three steps. First , we searched Medline and Embase databases between January 
2007 and February 2014 using a combinat ion of the following MeSH terms, t it le or abst ract  words, with no 
rest rict ion on the language of the art icles: (“ papillomavirus vaccine” , “ papil lomavirus vaccinat ion” , “ HPV 
vaccine” , or “ HPV vaccinat ion” ) and (“ program evaluat ion” , “ populat ion surveil lance” , “ sent inel 
surveil lance” , “ incidence” , or “ prevalence” ), and (“ papillomavirus infect ion” , “ condylomata acuminata” , 
“ anogenital warts” , “ cervical int raepithelial neoplasia” , “ cervical dysplasia” , “ uterine cervical neoplasm” , or 
“ HPV related diseases” ). We ident if ied eligible studies through reviewing t it les and abst racts and reviewed 
the bibliographies of eligible art icles. Second, we reviewed the abst racts of recent  maj or conferences on HPV 
(EUROGIN Congress 2013, Internat ional Papil lomavirus Conference 2012) to ident ify addit ional unpublished 
studies. Third, MD and MB contacted the authors of conference abst racts to obtain unpublished data. MD and 
EB independent ly assessed the eligibilit y of  all studies. In addit ion, DM independent ly assessed eligibilit y of  
studies on HPV infect ion. If  more than one publicat ion from the same data source and research team was 
available, we kept  t he publicat ion present ing the most  recent  data.  
 
Data ext ract ion and qualit y assessment  
Our main outcomes were the relat ive risks (RR) comparing the pre- and post -vaccinat ion periods for the: 1) 
prevalence of HPV infect ion for four HPV type subgroups:  high-oncogenic risk vaccine types (HPV-16/ 18), 
three types with t he greatest  evidence of cross-protect ive eff icacy (HPV-31/ 33/ 45);16 the f ive potent ially 
cross-protect ive types (HPV-31/ 33/ 45/ 52/ 58)16,  and all high-oncogenic risk (HR-HPV) non-vaccine types (all 
HR except  HPV-16/ 18); 2) f requency (prevalence or incidence) of AGW diagnosis; and 3) f requency 
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(prevalence or incidence) of high-grade cervical lesions. Two authors (MD and EB) independent ly ext racted 
the study characterist ics and outcomes using a standardized form. MD and MB contacted authors to request  
supplementary ext ract ions to standardize data st rat if icat ions between studies for comparison and pooling 
(e.g., same age and HPV type groupings). We also collected informat ion on the vaccinat ion program 
characterist ics and vaccinat ion coverage of the count ry/ region of each study (Appendix–Table S1). For t he 
HPV prevalence studies, we collected age-specif ic vaccinat ion coverage direct ly from each study, as 
vaccinat ion status was available for all study part icipants.  Finally, t he authors of each art icle validated the 
data from their study.  
 
Prior to contact ing the study invest igators, MD, AM, PLM and MB assessed whether t he studies had suff icient  
methodological qualit y to be included in the meta-analysis. The qualit y of the studies (potent ial for bias and 
confounding, and external validit y) was assessed independent ly from the invest igators of the original studies. 
Potent ial for bias and confounding within studies were assessed by reviewing the subj ects’  
select ion/ recruitment  procedures, endpoint  def init ions, algorit hms used to ident ify cases, and potent ial 
confounders considered in the stat ist ical analyses (Appendix-Tables S2-S4) 
 
Data analysis 
Because most ly young females (<20 years old) were vaccinated in the study populat ions, we decided a priori  
to st rat ify all our analyses by gender and age. Furthermore, because only t he quadrivalent  vaccine includes 
types HPV-6/ 11 (responsible for approximately 90% of AGW6), we decided a priori to st rat ify our analyses for 
AGW by the t ype of vaccine.  
 
To ensure comparabilit y of the study results included in the meta-analysis, we f irst  def ined pre- and post -
vaccinat ion periods for all studies (Appendix-Table S5). Second, for comparabilit y, we used prevalence or 
incidence rate rat ios as the measure of impact  for all HPV-related endpoints. For HPV infect ion, most  studies 
presented RR (crude and/ or adj usted prevalence rat ios) and 95% conf idence intervals (CI). When available, we 
included adj usted RR in the meta-analysis. When only crude HPV prevalence over t ime was available, we 
calculated prevalence rat ios by dividing the post - and pre-vaccinat ion prevalence and est imated the 95% CI 
(CI approximat ion for prevalence rat ios26) (Table 1).  For AGW and precancerous lesions, all studies presented 
yearly frequency (prevalence or incidence) over t ime. We est imated pre-vaccinat ion frequency by aggregat ing 
the data for up to t hree years prior to vaccinat ion, and calculated RR by dividing each post -vaccinat ion year 
by the pre-vaccinat ion est imate.  
 
We derived summary est imates of the impact  of HPV vaccinat ion for each endpoint  using random effect  
models on the log scale.27,28 We performed subgroup analysis to ident ify potent ial sources of heterogeneity by 
comparing the summary est imates obtained f rom subsets of studies and/ or groups within studies grouped by: 
YDFFLQHW\SHELYDOHQWTXDGULYDOHQWYDFFLQDWLRQFRYHUDJH/RZ+LJKVWXG\-specif ic coverage 
est imates for HPV infect ion, and count ry/ region-level coverage for the other outcomes), age (<20, 20-24, 25-
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29, 30-39 years), years since vaccinat ion program implementat ion (1,2,3,4 years), source of study data 
(populat ion-based, health provider/ insurance-based, clinic-based), and adj ustment  of the impact  measure 
(yes, no). We examined heterogeneity across studies using I2 and F2 stat ist ics28. I2 values less than 50%, 
between 50-75%, and more than 75% represent  low, substant ial and considerable heterogeneity, 
respect ively29. The p-value associated with the F2 stat ist ic represents the stat ist ical signif icance of 
heterogeneity. Finally, we examined dose-response between HPV vaccinat ion coverage (independent  variable) 
and the log RR of each study (dependent  variable) by f it t ing a linear regression, weighted by the inverse 
variances of the log RR30. We performed all analyses using Review Manager 5.2 and SAS 9.4.  
 
Role of the funding source 
The funding source had no role in the study design, data collect ion, analysis and interpretat ion, or writ ing of  
the report . MB had full access to all t he data in the study and had f inal responsibilit y for the decision to 
submit  for publicat ion. 
 
RESULTS 
We ident if ied 661 art icles and 29 conference abst racts, of which 20 records met  the inclusion crit eria (HPV 
infect ion (n=7)31-37, AGW (n=11)38-48, and high-grade cervical lesions49,50 (n=2)) (Figure 1). The studies were 
conducted in nine HICs and examined the populat ion-level impact  of vaccinat ion among 16,600 females for 
HPV infect ion, more than 125 million person-years of follow-up for AGW and 15 million female-years of 
follow-up for high-grade cervical lesions (Table 1). The vaccine used, vaccinat ion st rategy, delivery and 
vaccinat ion coverage varied substant ially (Table 1 and Appendix-Table S1). All studies had suff icient  
methodological qualit y to be included in the meta-analysis (Appendix-Tables S2-S4). However, because two 
studies examined the ent ire Danish populat ion over ident ical t ime periods,42,48 we only included the Baandrup 
et  al. study in our main analysis (the choice of study had no impact  on results, Appendix-Table S6).  
 
HPV infections 
Among females aged 14-19 years, t he overall prevalence of HPV-16/ 18 signif icant ly decreased, by 64% 
(RR=0·36, 95%CI[0·25;0·53]) compared to the pre-vaccinat ion period (Figure 2a), with a signif icant  dose-
response with vaccinat ion coverage (p=0·005). The overall prevalence of HPV-31/ 33/ 45 also signif icant ly 
decreased post -vaccinat ion by 28% (RR=0·72, 95%CI[0·54;0·96]), but  reduct ions were not  signif icant ly 
associated with vaccinat ion coverage. The overall prevalence of HPV-31/ 33/ 45/ 52/ 58 and non-vaccine HR 
types (i.e. all HR except  16/ 18) did not  change signif icant ly between the pre- and post -vaccinat ion periods.  
 
Among females aged 20-24 years, t he overall prevalence of HPV-16/ 18 decreased by 31% (RR=0·69, 
95%CI[0·47;1·01]) in the post -vaccinat ion period (Figure 2b). Alt hough the overall reduct ion in HPV-16/ 18 
infect ion was not  signif icant , a dose-response was observed with vaccinat ion coverage (p=0·01).  No signif icant  
declines in prevalence or dose-response with vaccinat ion coverage were observed for HPV-31/ 33/ 45 or HPV-
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31/ 33/ 45/ 52/ 58. Finally, t here was a small non-signif icant  increase in non-vaccine HR types (RR=1·09, 
95%CI[0·98;1·22]), which was negat ively associated with increasing vaccinat ion coverage (p=0·03).  
 
In addit ion to vaccinat ion coverage, t he use of adj usted or crude RRs emerged as a substant ial source of 
heterogeneity among studies (I2 between 50 and 75% for many endpoints, Figure 3). Interest ingly, the point  
est imate of adj usted RRs were lower than crude RRs for HPV subgroups with substant ial post -vaccinat ion 
reduct ions (i.e. , HPV-16/ 18 among 14-24 year olds, and HPV-31/ 33/ 45 among 14-19 year olds), but  were 
higher for the other endpoints.   
Anogenital warts diagnosis (AGW) 
Among females aged 15-19 years in count ries using the quadrivalent  vaccine, AGW decreased signif icant ly by 
31% (RR=0·69, 95%CI[0·60;0·79]). A st riking dose-response was observed between AGW reduct ion and increase 
in populat ion-level female vaccinat ion coverage (p=0·001) (Figure 4a). AGW were reduced by 61% (RR=0·39, 
95%CI[0·22;0·71]) in studies with high vaccinat ion coverage compared to a reduct ion of 14% (RR=0·86, 
95%CI[0·79;0·94]) in studies with low vaccinat ion coverage (Figure 5a). In addit ion to vaccinat ion coverage, 
years since the start  of  vaccinat ion emerged as a signif icant  source of heterogeneity (I2=68%, p=0·02) (Figure 
5a).  
 
Among older females (20-39 years) and young males (15-19 years) in count ries using the quadrivalent  vaccine, 
non-stat ist ically signif icant  decreases in AGW were observed post -vaccinat ion (11% (RR=0·89, 95%CI[0·79;1·02] 
and 5% (RR=0·95, 95%CI[0·84;1·08], respect ively) (Figure 4b,c). Again, there was a signif icant  dose-response 
between AGW reduct ions among older females and young males and increase in populat ion-level female 
vaccinat ion coverage (p=0·05 and 0·005, respect ively); and subgroup analyses revealed female vaccinat ion 
coverage as a main source of heterogeneity (I2=86%, p<0·008) (Figure 5b,c).  In count ries with high female 
vaccinat ion coverage, AGW were signif icant ly reduced by 32% (RR=0·68, 95%CI[0·51;0·89]) and 34% (RR=0·66, 
95%CI[0·47;0·91]) among older females and young males, respect ively. No changes in AGW were observed 
among older males (20-39 years) in count ries using the quadrivalent  vaccine.  
 
The only study examining populat ion-level changes in AGW following vaccinat ion with the bivalent  vaccine 
reported a small but  signif icant  decrease among females aged 15-19 years (RR=0·96, 95%CI[0·94;0·97]) (Figure 
4a). Conversely, a small but  signif icant  increase in AGW was observed among males aged 15-19 years (Figure 
4c), and there was no signif icant  effect  among older females and males (Figure 4b,d).  
 
Figure 6 il lust rates the changes over t ime in AGW in studies with the quadrivalent  vaccine, taking into 
considerat ion the main sources of heterogeneity. Figure 6a clearly il lust rates that  there was a rapid and 
signif icant  decline over t ime in AGW for females aged <30 years old in studies with high vaccinat ion coverage. 
However, in studies with low vaccinat ion coverage (Figure 6b), the decline was observed only among females 
<20 years old, and became signif icant  only in the third year following vaccinat ion implementat ion. There was 
also a rapid and signif icant  decline over t ime in AGW for males aged <30 years old in studies with high female 
8 
 
vaccinat ion coverage (Figure 6c). However, t here was a general t endency of increasing AGW for older males in 
studies with low female vaccinat ion coverage (Figure 6d).  
 
High-grade precancerous cervical lesions 
A signif icant  decrease in high-grade lesions was observed in t he only study report ing data among females aged 
15-19 years (RR=0·69, 95%CI[0·66;0·73]),  but  there was no signif icant  change in the two studies report ing data 
among older females (Appendix-Figure S1).  
 
DISCUSSION 
This systemat ic review and meta-analysis, represent ing more than 140 million person-years of follow-up data 
from nine HIC, reports signif icant  populat ion-level decreases in HPV-related outcomes up to four years after 
the start  of  HPV vaccinat ion programs. In count ries with high vaccinat ion coverage, HPV-16/ 18 infect ion and 
AGW decreased by more than 60% in females younger than 20 years of age, start ing after t he f irst  year of the 
programs. Furthermore, in these count ries, our result s suggest  that  there is evidence of vaccine cross-
protect ion and herd effect s, with signif icant  reduct ions in HPV-31/ 33/ 45 infect ion among females younger 
than 20 years of age, and AGW among males and older females, respect ively. In count ries with low 
vaccinat ion coverage, signif icant  reduct ions were observed for HPV-16/ 18 infect ion and AGW among young 
females, but  no signif icant  reduct ions were observed for HPV-31/ 33/ 45 among young females or HPV-related 
outcomes among males and older females (i.e. ,  no indicat ion of cross-protect ion or herd effects). Our f indings 
provide st rong evidence that  HPV vaccinat ion is highly effect ive and can provide cross-protect ion outside t rial 
set t ings, and reinforce the need for early vaccinat ion and high vaccinat ion coverage to maximize populat ion-
level effect iveness and herd effects. 
 
Although this meta-analysis is based on t ime-t rend ecological studies, and thus causalit y cannot  be concluded, 
several factors st rongly suggest  that  the reported reduct ions in populat ion-level HPV-related outcomes can be 
at t ributed to HPV vaccinat ion: 1) magnitude of the effect , 2) dose-response relat ionship between vaccinat ion 
coverage and effect , and 3) consistency between the studies included in t he review despite dif ferent  methods 
and set t ings, and consistency with results from clinical t rials and mathemat ical modeling. First ly, reduct ion in 
HPV-16/ 18, AGW and high-grade cervical lesions were large and stat ist ically signif icant  in the target  age 
groups for vaccinat ion (females <20 years). Secondly, there was a stat ist ically signif icant  posit ive associat ion 
between increases in vaccinat ion coverage and reduct ion in HPV-16/ 18 infect ion among young females and 
AGW among both females and males. Furthermore, reduct ions in AGW increased over t ime since vaccinat ion 
(as the number of vaccinated cohorts increased), especially in youngest  age groups with highest  vaccinat ion 
coverage. Thirdly, t here was consistency in results between count ries with similar levels of vaccinat ion 
coverage. Furthermore, in the studies where the vaccine status was available, vaccinated females had 
signif icant ly lower HPV-related outcomes than unvaccinated females in the post -vaccinat ion era. 32-34,37,41,51-54 
Our results are also consistent  with data from clinical t rials that  demonst rated a high vaccine-t ype 
eff icacy,11,12 and suggested some degree of cross-protect ion against  HPV-31/ 33/ 45 but  not  against  HPV-
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52/ 58.16 However, t he higher bivalent  cross-protect ive eff icacy reported in a recent  meta-analysis of clinical 
t rial data16 was not  observed in our populat ion-level meta-analysis (Figure 3). Finally the large herd effects 
observed with high vaccinat ion coverage are consistent  with predict ions from dynamic model.20-24 
   
The studies included in the meta-analysis possess the st rengths and weaknesses inherent  in ecological studies. 
They provide a wealth of t imely informat ion on the impact  of HPV vaccinat ion using large study populat ions, 
but  are part icularly vulnerable to informat ion bias and confounding (Appendix-Tables S2-S4). However, the 
three most  important  potent ial sources of bias and confounding in t hese studies are likely to underest imate 
the impact  of vaccinat ion. First ly, due to increased awareness of AGW from licensing of the HPV vaccines and 
the launch of t he vaccinat ion programs, there is potent ial for confounding related to possible increases in 
health seeking behaviours and informat ion bias from increased diagnosis of AGW over t ime. Secondly, most  
studies had insuff icient  or no informat ion to adequately cont rol for sexual act ivit y, which may have been 
increasing over t ime.42, 55, 56 These limitat ions may explain t he slight  increase in the prevalence of non-vaccine 
HR types and AGW consultat ions in the post -vaccinat ion period within groups with low or no vaccinat ion 
coverage (e.g., older females and males) (Figures 2b and 6). Thirdly, there is potent ial for informat ion bias 
due to masking by HPV-16/ 18, part icularly in t he pre-vaccine period.57 That  is, by prevent ing HPV-16/ 18 
infect ion, vaccinat ion could remove the potent ial masking effect  of these types, producing increased 
detect ion of non-vaccine t ypes. Conversely, the main potent ial source of overest imat ion of vaccinat ion 
impact  is present  in clinic-based studies measuring the proport ion of consultat ions at t ributable to AGW in 
sexual health clinics (Appendix-Table S3).38,41 Indeed, changes in the clientele between pre- and post -
vaccinat ion periods could overest imate vaccinat ion impact  on AGW if  consultat ions due to other causes 
increased (e.g., chlamydia consultat ions41). Clinic-based studies represent  two thirds of the studies examining 
the populat ion-level impact  of vaccinat ion on AGW in count ries with high vaccinat ion coverage, and may 
part ly explain slight  reduct ions in AGW among older males (Figure 6). Fourthly,  the external validit y of the 
studies was generally good (Appendix-Table S2-S4). However, because most  studies were among individuals 
consult ing the health system, HPV vaccinat ion impact  results may not  be completely generalizable to groups 
with lower health seeking behaviour, part icularly in count ries where HPV vaccine is delivered in healthcare 
clinics. Finally, given the indirect  nature of our inferences, our analysis may not  have the adequate sensit ivit y 
to detect  small post -vaccinat ion effects (e.g., t ype-replacement , or herd effects and cross-protect ion when 
vaccinat ion coverage is low).    
 
Our results should be interpreted caut iously as they represent  the short -term populat ion-level impact  of HPV 
vaccinat ion programs. First ly, t he cohorts of vaccinated girls have not  reached the ages with highest  
incidence rates of HPV infect ion, AGW and cervical lesions (i.e., between 20 and 35 years of age). Therefore, 
the direct  and herd impact  are expected to cont inue to increase over t ime (Figure 6) as overall populat ion-
level vaccinat ion coverage increases. Secondly, there is current ly insuff icient  evidence to draw conclusions 
about  the existence of net  type-replacement  (e.g., no signif icant  increase in t he prevalence of HR non-
vaccine types among groups with highest  vaccinat ion coverage). This may be because there is no type 
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replacement , or part ly due to the short  follow-up t ime or dilut ion of type-specif ic changes by grouping HPV-
types. Thirdly, t he t ime horizon was too short  to examine waning of vaccine eff icacy. However, randomized-
cont rol t rials have shown no signs of waning vaccine eff icacy after 9·5 years of follow-up.58 Fourthly, given 
the long lag t ime between infect ion and cancer, t here is current ly no available direct  evidence of the impact  
of vaccinat ion on HPV-related cancers. However, given that  HPV infect ion is the cause, and high-grade 
precancerous cervical lesions the precursors of cervical cancer, these intermediate outcomes have been 
deemed acceptable proxies for eff icacy against  cervical cancer by regulatory bodies worldwide.59-62 
Nevertheless, one should be careful in using reduct ions in precancerous cervical lesions from screening 
databases as proxies for cervical cancer as 1) they may ref lect  changes in screening recommendat ions and 
part icipat ion, and 2) they are not  HPV type-specif ic. In addit ion, surveil lance studies based on cervical 
screening regist ries may overest imate the populat ion-level impact  of HPV vaccinat ion, if  vaccine uptake is 
higher among women who get  screened.63-66 Finally, as previously shown, HPV-6/ 11-related disease (e.g.,  
AGW) t rends are a poor proxy of change in HPV-16/ 18 and it s related diseases (e.g., cervical cancer).67 This is 
because HPV-6/ 11 will be easier to eliminate and cont rol t hrough vaccinat ion than HPV-16/ 18 due to it s 
shorter durat ions of infect iousness and/ or lower t ransmissibilit y.  
 
Our overall f indings are likely generalizable to HIC as most  of the heterogeneity between count ries 
disappeared once results were st rat if ied by vaccinat ion coverage and age (Figures 3 and 5),  and given 
similarit ies in sexual behavior,56 HPV type dist ribut ion,68,69 age prof ile of HPV prevalence,70 and cervical 
cancer incidence between HIC.71 However, precise est imates of populat ion-level impact  wil l vary between 
count ries according to their programmat ic specif icit ies, such as the characterist ics of catch-up campaigns. 
Our results should be ext rapolated to LMIC with caut ion as all studies in t he meta-analysis were from HIC and 
given dif ferences between HIC and LMIC in sexual behavior,56 HPV epidemiology70,71 and potent ial cofactors of 
HPV infect ion and disease, such as high HIV prevalence.72 However, t here is no evidence to suggest  t hat  
vaccine eff icacy would be lower in LMIC, part icularly because the vaccine has been shown safe and 
immunogenic among HIV infected women.73 On the other hand, herd effects may dif fer in LMIC with very 
dif ferent  populat ion-level sexual behaviour (e.g., greater mixing between older men and younger women, 
more concurrency in partnerships). Even in t he unlikely scenario that  t here would be no herd effects in LMICs, 
a recent  global modeling study has shown that  HPV vaccinat ion would be highly cost -effect ive, given very high 
cervical cancer incidence and mortalit y in t hese count ries (PRIME).19 
 
This f irst  meta-analysis of the populat ion-level impact  of HPV vaccinat ion programs shows compelling 
evidence of a st rong and stat ist ically signif icant  dose-response between HPV vaccinat ion coverage and 
reduct ions in HPV-16/ 18 infect ion and AGW among females targeted for vaccinat ion. In addit ion, our study 
provides the f irst  evidence of a dose-response between female vaccinat ion coverage and reduct ion of AGW in 
older females and males. Our results have important  policy implicat ions. The sharpest  declines in HPV-related 
outcomes in females and males were observed in count ries with school-based vaccine delivery (e.g., U.K.,  
Aust ralia, New Zealand), suggest ing that  t his st rategy facilitates faster roll-out  and higher vaccinat ion 
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coverage. The study also shows populat ion-level data support ing clinical-t rial evidence of HPV vaccine cross-
protect ion against  HPV-types 31/ 33/ 45, though no dose-response was seen with vaccinat ion coverage.  
 
In conclusion, t he results of this study are very promising for the long-term populat ion-level impact  of HPV 
vaccinat ion programs on cervical cancer and other HPV-related diseases. However, it  is important  to cont inue 
monitoring and evaluat ing HPV vaccinat ion programs to conf irm these results and to remain vigilant  for 
evidence of potent ial waning eff icacy, t ype-replacement  or lower vaccinat ion coverage amongst  groups at  
greater risk of HPV-related cancers. 
 
PANEL: RESEARCH IN CONTEXT 
Systematic review 
To undertake this meta-analysis we performed a systemat ically review to ident ify all t ime-t rend studies 
examining changes, between the pre- and post -vaccinat ion periods, in the incidence/ prevalence of at  least  
one HPV-related endpoint :  HPV infect ion, anogenital warts (AGW), and high-grade cervical lesions. We 
searched Medline and Embase databases between January 2007 and February 2014 using a combinat ion of the 
following MeSH terms, t it le or abst ract  words, with no rest rict ion on the language of the art icles: 
(“ papil lomavirus vaccine” ,  “ papillomavirus vaccinat ion” , “ HPV vaccine” , or “ HPV vaccinat ion” ) and 
(“ program evaluat ion” ,  “ populat ion surveillance” ,  “ sent inel surveillance” , “ incidence” , or “ prevalence” ), and 
(“ papil lomavirus infect ion” , “ condylomata acuminata” , “ anogenital warts” , “ cervical int raepithelial 
neoplasia” , “ cervical dysplasia” , “ uterine cervical neoplasm” , or “ HPV related diseases” ). We also reviewed 
the abst racts of recent  maj or conferences on HPV (EUROGIN Congress 2013, Internat ional Papillomavirus 
Conference 2012) to ident ify addit ional unpublished studies. Twenty records, f rom nine high income 
count ries, met  t he inclusion crit eria (HPV infect ion (n=7)31-37, AGW (n=11)38-48, and high-grade cervical 
lesions49,50 (n=2)) 
 
Interpretation 
This meta-analysis showed, for the f irst  t ime, a st rong and stat ist ically signif icant  dose-response between HPV 
vaccinat ion coverage and populat ion-level reduct ions in HPV-related outcomes among young females. In 
count ries with KLJKIHPDOHYDFFLQDWLRQFRYHUDJH, HPV-16/ 18 infect ion and AGW declined by more than 
60% in females younger than 20 years. Furthermore, t he study provides the f irst  evidence of a dose-response 
between vaccinat ion coverage and herd effects. In count ries with high female vaccinat ion coverage, AGW 
among young male and older females declined by 20-30%. Finally, t he study showed stat ist ically signif icant  
declines in HPV-types 31/ 33/ 45 among young females, which is suggest ive of cross-protect ion. 
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Table 1. Characteristics of the studies included in the systematic review and meta-analysis 
Author 
(Country) 
Vaccine 
used  
Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect 
measure in 
publication 
Effect 
measure 
recalculated¥  
HPV infection          
Cummings 2012 
(U.S.) 
Quadrivalent  Clinic-based Females 14-17 yrs 
at tending 1 of 3 
urban primary care 
clinics in 
Indianapolis 
 
Females 14-17 yrs Prevaccine:1999-2005 
Postvaccine:2010 
N prevaccine:150 
N postvaccine:75 
HPV+ Roche Linear 
Array (Roche, 37 
types) 
OR of HPV 
prevalence 
(crude) 
RR of HPV 
prevalence 
(crude) 
Kahn 2012 
(U.S.) 
Quadrivalent  Clinic-based Females 13-26 yrs 
at tending 1 
hospital-based 
adolescent  clinic 
and 1 community 
health center in 
Cincinnat i 
 
Females 13-24 yrs, 
Had had sexual 
contact  
 
Prevaccine:2006-2007 
Postvaccine:2009-2010 
N prevaccine:336 
N postvaccine:383 
HPV+ Roche Linear 
Array (Roche, 37 
types) 
HPV 
prevalence 
dif ference 
(adj usted)  
RR of HPV 
prevalence 
(adj usted) 
Tabrizi 2012 
(Aust ralia) 
Quadrivalent  Clinic-based Females 18-24 yrs 
at tending 1 of 6 
family planning 
clinics in Sydney, 
Melbourne, Perth 
 
Females 18-24 yrs 
 
Prevaccine:2005-2007 
Postvaccine:2010-2011 
N prevaccine:202 
N postvaccine:1,058 
 
HPV+ Roche Linear 
Array (13 types),   
 
OR of HPV 
prevalence 
(adj usted) 
RR of HPV 
prevalence 
(adj usted) 
Markowitz 2013 
(U.S.) 
Quadrivalent  Populat ion-
based: NHANES 
study 
part icipants  
Nat ionally 
representat ive 
sample of US 
females aged 14-59 
yrs 
 
Females 14-24 yrs 
 
Prevaccine:2003-2006 
Postvaccine:2007-2010 
N prevaccine:1,795 
N postvaccine:1,185 
HPV+ Roche Linear 
Array (Roche, 37 
types) 
RR of HPV 
prevalence 
(crude) 
RR of HPV 
prevalence 
(crude) 
Mesher 2013 
(England) 
Bivalent  Clinic-based Females 16-24 yrs 
undergoing 
chlamydia screening 
in community sexual 
health services, 
general pract ice, 
youth clinics in 7 
regions around 
England 
Females 16-24 yrs Prevaccine:2008 
Postvaccine:2010-2012 
N prevaccine:2,354 
N postvaccine:4,178 
2008: Hybrid Capture 
2 and Roche Linear 
Array 
2010-2012: HPV+ In-
house mult iplex PCR 
and Luminex-based 
genotyping test  (18 
types)ۅ௘ 
 
OR of HPV 
prevalence 
(adj usted) 
RR of HPV 
prevalence 
(adj usted) 
Sonnenberg 
2013 (England, 
Scot land, 
Wales) 
Bivalent  Populat ion-
based: NATSAL 
study 
part icipants 
Nat ionally 
representat ive 
sample of males and 
females aged 16-74 
yrs in Britain 
 
Females 18-24 yrs Prevaccine:1999-2001 
Postvaccine:2010-2012 
N prevaccine:328 
N postvaccine:795 
HPV+ In-house 
Luminex-based 
genotyping assay (18 
types)ۅ௘ in urine 
samples 
OR of HPV 
prevalence 
(age-adj usted) 
RR of HPV 
prevalence 
(crude) 
Kavanagh 2014 
(Scot land) 
Bivalent  Populat ion-
based: Scot t ish 
Cervical 
screening Call & 
Females 20-21 yrs 
part icipat ing in 
rout ine cervical 
cancer screening in 
Females 20-21 yrs Prevaccine:2009-2010 
Postvaccine:2011-2012 
N prevaccine:2,704 
N postvaccine:1,975 
 
HPV+ Mult imet rix 
HPV assay (18 types) 
HPV 
prevalence 
over t ime (no 
effect  
RR of HPV 
prevalence 
(crude) 
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Author 
(Country) 
Vaccine 
used  
Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect 
measure in 
publication 
Effect 
measure 
recalculated¥  
Recall System  Scot land measure) 
Anogenital warts    
Oliphant  2011 
(New Zealand) 
Quadrivalent  Clinic-based New clients of 1 
sexual health 
service in Auckland 
aged \UV 
Females and 
males 15-39 yrs 
 
2007-2010 
Prevaccine:2007-2008 
Postvaccine:2009-2010 
P-yr prevaccine: 
17,517 
P-yr postvaccine: 
15,508 
 
Clinical diagnosis Annual 
proport ion of 
new clients 
diagnosed 
with AGW 
RR of AGW 
proport ion 
(crude) 
Bauer 2012 
(U.S.) 
Quadrivalent  Health provider 
/ insurance-
based: Clinical 
encounters 
claims data of a 
health program 
 
Clients of the 
California Family 
Planning access care 
& t reatment  
program aged 
yrs (87% are 
females) 
Females and males 
15-39 yrs  
Program serves low-
income individuals 
 
2007-2010 
Prevaccine: 2007 
Postvaccine:2008-2010 
P-yr prevaccine: 
1,750,980 
P-yr postvaccine: 
5,555,420 
 
ICD-9 codes 078.10, 
078.11 OR 
prescript ion of 
Imiquimod or 
Podophyllotoxin 
Annual 
proport ion of 
PACT clients 
diagnosed with 
AGW 
RR of AGW 
proport ion 
(crude) 
Kliewer 2012 
(Canada) 
 
Quadrivalent  Populat ion-
based: 
Medical claims 
and hospital 
discharge 
database 
 
Ent ire populat ion of 
Manitoba 
Females and 
males  
15-39 yrs 
1985-2009 
Prevaccine: 2006-2008 
Postvaccine:2009 
 
P-yr prevaccine: 
737,366 
P-yr postvaccine: 
250,984 
 
Treatments (one of 
14 tarif f  codes for 
AGW t reatments) OR 
hospitalizat ion for 
AGW with ICD-9 code 
078.11 OR 078.1, 
078.10, 078.19 and 
related procedure 
OR ICD-10 A630 OR 
B07 and related 
procedure 
Annual 
incidence rate 
of diagnosed 
AGW in the 
populat ion 
RR of AGW 
incidence 
(crude) 
Leval 2012 
(Sweden) 
Quadrivalent  Populat ion-based: 
Stat ist ics Sweden, 
Nat ional Pat ient  
Register,  
Prescribed Drug 
Register 
Ent ire populat ion of 
Sweden aged 
yrs 
Females and 
males 
15-39 yrs 
2006-2010 
Prevaccine: 2006 
Postvaccine:2007-2010 
 
P-yr prevaccine: 
2,942,525 
P-yr postvaccine: 
12,043,886 
 
ICD-10 code A63.0 
OR  prescript ion of 
Imiquimod or 
Podophyllotoxin  
Annual 
incidence rate 
of diagnosed 
AGW in the 
populat ion 
RR of AGW 
incidence 
(crude) 
Ali 2013 
(Aust ralia) 
Quadrivalent  Clinic-based  New clients of 8 
sexual health 
centers across 
Aust ralia aged 
yrs 
(Aust ralian born) 
Aust ralian born 
females and males 
15-39 yrs 
2004-2011 
Prevaccine: 2005-2007 
Postvaccine:2008-2012 
 
P-yr prevaccine: 
24,147 
P-yr postvaccine: 
37,237 
 
Clinical diagnosis Annual 
proport ion of 
new clients 
with 
diagnosed 
AGW 
RR of AGW 
proport ion 
(crude) 
Baandrup 2013 
(Denmark) 
Quadrivalent  Populat ion-based: 
Stat ist ics 
Denmark, 
Nat ional Pat ient  
Regist ry 
 
Ent ire populat ion of 
Denmark \UV 
 
Females and 
males  
15-39 yrs 
 
2006-2011 
Prevaccine: 2007-2009 
Postvaccine:2010-2011 
 
 
 
P-yr prevaccine: 
5,140,633 
P-yr postvaccine: 
2,598,265 
 
ICD-10 code A63.0  Annual 
incidence rate 
of diagnosed 
AGW in the 
populat ion 
RR of AGW 
incidence 
(crude) 
Howell-Jones 
2013 (England) 
 
Bivalent  Populat ion-based: 
Genitourinary 
medicine (GUM) 
Ent ire populat ion of 
England aged 15-24 
yrs; 
Females and 
males 
15-24 yrs 
2002-2011 
Prevaccine: 2006-2008 
Postvaccine:2009-2011 
P-yr prevaccine: 
6,790,231 
P-yr postvaccine: 
Clinical diagnosis  
 
Annual 
incidence rate 
of diagnosed 
RR of AGW 
incidence 
(crude) 
Annual incidence rate of diagnosed AGW in the populat ion 
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Author 
(Country) 
Vaccine 
used  
Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect 
measure in 
publication 
Effect 
measure 
recalculated¥  
clinics  
 
  20,610,282 
 
AGW in the 
populat ion 
Flagg 2013 
(U.S.) 
Quadrivalent  Health provider 
/ insurance-
based: Truven 
Health Analyt ics 
Market  Scan 
Commercial 
Claims and 
Encounters 
Database 
Enrollees in 
approximately 100 
health private 
insurance plans 
across the U.S. aged 
10-39 yrs 
Females and 
males 
15-39 yrs,  
Insured 
employees, early 
ret irees and their 
dependents 
2003-2010 
Prevaccine: 2004-2006 
Postvaccine:2007-2010 
 
P-yr prevaccine: 
11,864,207 
P-yr postvaccine: 
36,000,783 
 
1) ICD-9 codes 
078.11 OR 2) ICD-9 
code 078.1, 078.10, 
or 078.19 and 
therapeut ic 
procedure or 
diagnosis of benign 
anogenital neoplasm 
OR 
prescript ion for AGW 
t reatment  and 
therapeut ic 
procedure or 
diagnosis of benign 
anogenital neoplasm 
  
Annual 
proport ion of 
insured 
individuals 
with 
diagnosed 
AGW 
RR of AGW 
proport ion 
(crude) 
Mikolaj czyk 
2013 
(Germany) 
 
Quadrivalent  Health provider 
/ insurance-
based: German 
Pharmacoepide
miological 
Research 
Database 
 
Enrollees in 1 large 
health insurance 
company across 
Germany aged 10-79 
yrs 
Females and 
males 
15-39 yrs 
2005-2008 
Prevaccine: 2005-2007 
Postvaccine:2008 
 
P-yr prevaccine: 
4,439,256 
P-yr postvaccine: 
1,621,308 
 
ICD-10 code A63.0 Annual 
incidence rate 
of diagnosed 
AGW among 
insured 
individuals 
RR of AGW 
incidence 
(crude) 
Nsouli-Maktabi 
2013 (U.S.) 
Quadrivalent  Health provider 
/ insurance-
based: Defense 
Medical 
Surveillance 
System 
Members of the U.S. 
Armed Forced 
across the U.S. aged 
\UV 
Females and 
males 17-39 yrs,  
Member of the 
Forces any t ime 
between 2000-
2012 
 
2000-2012 
Prevaccine: 2004-2006 
Postvaccine:2007-2011 
 
P-yr prevaccine: 
3,569,823 
P-yr postvaccine: 
4,736,303 
 
ICD-9 code 078.1 Annual 
incidence rate 
of diagnosed 
AGW among 
US force 
members 
RR of AGW 
incidence 
(crude) 
Sandø 2013 
(Denmark) 
 
Quadrivalent  Populat ion-based: 
Stat ist ics 
Denmark, 
Nat ional Pat ient  
Regist ry,  
Medical 
Products 
Stat ist ics 
Regist ry 
Ent ire populat ion of 
Denmark aged 15-34 
yrs 
Females and 
males  
15-34 yrs 
2001-2011 
Prevaccine: 2007-2009 
Postvaccine:2010-2011 
 
P-yr prevaccine: 
1,326,573 
P-yr postvaccine: 
2,687,020 
 
ICD-10 code A63.0, 
OR prescript ion of 
Podophyllotoxin 
Annual 
proport ion of 
the populat ion 
with diagnosed 
AGW 
RR of AGW 
proport ion 
(crude) 
High-grade precancerous cervical lesions  
Brotherton 
2011/  
Aust ralian 
Inst itute of 
Health and 
Quadrivalent  Health provider 
/ insurance-
based: Cervical 
cancer 
screening 
Females aged <69 
yrs part icipat ing in 
the Nat ional 
Cervical Screening 
Program 
Females 
15-39 yrs 
2004-2011 
Prevaccine:2005-2007 
Postvaccine:2008-2011 
P-yr prevaccine: 
6,028,918 
P-yr postvaccine: 
7,814,102 
Histopathologically 
conf irmed CIN2+ 
 
Annual 
incidence of 
high grade 
cervical 
lesions among 
RR of high 
grade lesion 
incidence 
(crude) 
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Author 
(Country) 
Vaccine 
used  
Data source* Study population Population used 
in meta-analysis 
Data collection dates† Sample size used in 
meta-analysis ‡ 
Case definition Effect 
measure in 
publication 
Effect 
measure 
recalculated¥  
Welfare 2013 
(Aust ralia) §௘ 
 
program regist ry screened 
females 
 
Niccolai 2013 
(U.S.) 
Quadrivalent  Health provider 
/ insurance-
based: 
Statewide 
surveillance (all 
34 pathology 
laboratories 
report  
CIN2+/ AIS) 
Females aged 21-39 
yrs from 
Connect icut   
screened for 
cervical cancer  
Females 
21-39 yrs 
2008-2011 
Prevaccine:2008 
Postvaccine:2009-2011 
P-yr prevaccine: 
 411,624 
P-yr postvaccine: 
823,248 
 
 
Histopathologically 
conf irmed CIN2+ 
 
Annual 
incidence of 
high grade 
lesions among 
females 21-39 
yrs in 
Connect icut   
RR of high 
grade lesion 
incidence 
(crude) 
 
OR: Odds rat io;  RR: Relat ive risk (Post -vaccinat ion prevalence or incidence /  Pre-vaccinat ion prevalence or incidence) 
* Data sources are considered as: 1) Populat ion-based when the study populat ion includes the total populat ion of a given count ry/ region, 2) Health 
provider/ insurance-based when the study populat ion is const ituted of a subgroup of the total populat ion part icipat ing in a specif ic health program or insurance 
plan, 3) Clinic-based when the study populat ion is const ituted of a limited number of clinics or hospital’ s clients. 
†
 For studies on HPV infect ion, the pre- and post -vaccinat ion periods were already determined in original publicat ions (except  for Kavanagh et  al.).  For studies on 
AGW and cervical lesions studies, the pre- and post-vaccinat ion periods were determined for the purpose of this systemat ic review as described in the Appendix- 
Table S5.    
‡
 The sample size is rest ricted to the age groups used in the review. For studies on HPV infect ion, the pre and post -vaccinat ion sample sizes were already 
determined in original studies. For studies on AGW and cervical lesions, the pre-vaccinat ion sample size corresponds to the cumulat ive number of person-years up 
to three years pre-vaccinat ion, including the year of the int roduct ion of HPV vaccinat ion. The post -vaccinat ion sample size corresponds to the cumulat ive number 
of person-years from 1 to 4 years after the int roduct ion of vaccinat ion, depending on data available in each study. 
§௘ Data from Brotherton et  al.  201149 are rest ricted to the Victorian regist ry data. Supplementary data from the Aust ralian Inst itute of Health and Welfare 2013 
report  74 were provided by Dr. Brotherton. Since the report  covers all regions of Aust ral ia,  it  was used as our main data source for the review.   ۅ௘
 13 HR-HPV types were presented in the original publicat ions whereas the 18 HR-HPV types available were used for the purposes of this meta-analysis 
¥ For HPV infect ion, the invest igators recalculated the RR of prevalence using the original data from their specif ic studies. For AGW and precancerous lesions, we 
est imated pre-vaccinat ion frequency by aggregat ing the data for up to three years prior to vaccinat ion, and calculated RR by dividing each post -vaccinat ion year 
by the pre-vaccinat ion est imate 
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Figure 1. Flowchart of study selection. 
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Figure 2. Changes in the prevalence of HPV infections between the pre- and post-vaccination periods 
among females aged 13-24 years old, ranked by age-VSHFLILFYDFFLQDWLRQFRYHUDJHGRVHUHSRUWHGLQ
studies. 
A) Females 13-19 years old§ 
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B) Females 20-24 years old 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NA: Not  available; RR: Relat ive risk; CI: Confidence interval;  HR: High-risk 
p-value for t rends obtained by f it t ing a linear regression between the log RR and the age-specif ic coverage of each study, 
weighted by the inverse variances of the log  RR: Females 13-19 years old, HPV16/ 18 p=0.005; HPV 31/ 33/ 45 p=0.14; 
HPV31/ 33/ 45/ 52/ 58 p= 0.69; HPV HR except  16/ 18 p=0.60, Females 20-24 years old, HPV16/ 18 p=0.01; HPV 31/ 33/ 45 
p=0.63; HPV31/ 33/ 45/ 52/ 58 p= 0.46; HPV HR except  16/ 18 p=0.03 
§ The minimum age of part icipants varied between studies (see Table 1) 
* Age-VSHFLILFSURSRUWLRQRIIHPDOHVLQFOXGHGLQWKHDQDO\VLVRIHDFKVWXG\ZKRUHFHLYHGGRVHRIWKH+39YDFFLQH 
†
  
Data not  available for females 13-19 years old in Kavanagh et  al.,  and for females 20-24 years old in Cummings et  al.  
‡ Data not  provided because they were considered as potent ially unreliable according to NHANES analyt ic guidelines70:   
Prevalence est imates had a relat ive standard error (RSE) of >30% and the sample size was below the recommended 
sample size for analyses of complex survey data, by design effect  and specif ied proport ion. To be consistent  throughout  
the studies using complex survey designs, we excluded data not  meet ing the recommended sample size for analyses of 
complex survey data, by design effect  and specif ied proport ion. The only data excluded was for HPV31-33-45 from 
NATSAL: unweighted pre-vaccinat ion prevalence: 3/ 85; unweighted post -vaccinat ion:16/ 215; weighted prevalence rat io:  
3.50 (0.97-12.67).  
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Figure 3. Subgroup analyses of the changes in the prevalence of HPV infections between the pre- and 
post-vaccination periods among females. 
A) Females 13-19 years old 
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B) Females 20-24 years old 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NA: Not  available; RR: Relat ive risk; CI:  Confidence interval; HR: High-risk 
 
  
26 
 
Figure 4. Changes in AGW diagnosis between the pre- and post-vaccination periods among females and 
males aged 15-39 years old, ranked by the national/setting-specific females’ vaccination coverage.  
A) Females 15-19 years old 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) Females 20-39 years old 
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C) Males 15-19 years old 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D) Males 20-39 years old 
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RR: Relat ive risk; CI:  Confidence interval 
p-value for t rends obtained by f it t ing a linear regression between the log RR and the rank of vaccinat ion coverage of each 
study, weighted by the inverse variances of the log  RR : Females 15-19 years old: p=0.001; Females 20-39 years old: 
p=0.05; Males 15-19 years old: p=0.005; Males 20-39 years old: p=0.06 
 
*  Before vaccinat ion: Cumulat ive number of cases and person-years up to three years pre-vaccinat ion, including the year 
of the int roduct ion of HPV vaccinat ion.  
†
  After vaccinat ion: Cumulat ive number of cases and person-years from 1 to 4 years after the int roduct ion of 
vaccinat ion, depending on data available in each study. 
‡
  Years of post -vaccinat ion follow-up: Number of years after the int roduct ion of HPV vaccinat ion considered in the 
meta-analysis (see Appendix-Table S5 for more details). 
§
  Studies were qualitat ively ranked by the nat ional/ set t ing-specif ic vaccinat ion coverage, by considering the number of 
cohorts vaccinated and vaccinat ion coverage achieved in each cohort .  However, it  was not  possible to est imate the 
overall vaccinat ion coverage for each study (see Appendix-Table S1 for details about  the program descript ion, number 
of cohorts vaccinated and 3-dose vaccinat ion coverage for each study). 
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Figure 5. Subgroup analyses of the changes in AGW diagnosis between the pre- and post-vaccination 
periods among females and males (NOTE: data are for years with female only vaccination programs).  
A) Females 15-19 years old 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) Females 20-39 years old 
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C) Males 14-19 years old 
 
 
 
 
 
 
 
 
 
 
 
 
 
D) Males 20-39 years old 
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Figure 6. Changes in AGW diagnosis among females and males during the first four years after the introduction of HPV vaccination with the 
quadrivalent vaccine, stratified for age and females’ vaccination coverage.  
A) Females – +LJKIHPDOHFRYHUDJH*      B) Females – Low female coverage (<50%) † 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) C) Males - +LJKIHPDOHFRYHUDJH*      D) Males – Low female coverage (< 50%) †  
  
32 
 
*  High coverage: the results from the following studies were combined depending on the years of follow-up available: Year 1 and 2: Oliphant  2011, Baandrup 2013, 
Ali 2013; Year 3 and 4: Ali 2013 (see Appendix-Table S1 for informat ion about  each study vaccinat ion coverage). 
†
 
   Low coverage: the results from the following studies were combined depending on the years of follow-up available: Year 1 :  Leval 2013, Kliewer 2012, Flagg 2013, 
Nsouli-Maktabi 2013, Mikolaj czyk 2013; Year 2, 3, 4 : Leval 2013, Flagg 2013, Nsouli-Maktabi 2013; Bauer 2013 (see Appendix-Table S1 for informat ion about  each 
study vaccinat ion coverage). 
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Table S1. Description of HPV vaccination programs and vaccination coverage for each study country/region 
Country Vaccine used Financing Availability of vaccine / 
Program start 
Program description* 3 doses Vaccination coverage (year)† 
Australia Quadrivalent Public April 2007  
 
 
 
 
 
 
 
School-based program:  
x Girls 12-13 yrs 
x Boys 12-13 yrs since February 2013 
 
School-based catch-up: 
x Girls 14-17 yrs (2007-2009) 
x Boys 14-15 yrs (2013-2014) 
 School-based program:  
x Girls 12-13 yrs: 71% (2012) 
x Boys 12-13: NA  
 
School-based catch-up: 
x Girls 14-17 yrs:70% (2012) 
x Boys 14-15 yrs: NA 
   July 2007 GP/Community catch-up:  
x Women 18-26 yrs (2007-2009) 
 
GP/Community catch-up:  
x Women 18-19 yrs: 69% (2012) 
x Women 20-26 yrs: 44% (2012)‡ 
Canada 
(Manitoba) 
 
Quadrivalent Private  
 
 
August 2006 (vaccine 
available privately) 
Private vaccination: 
x Girls/women 9-26 yrs 
Private vaccination: 
x Girls/women 9-26 yrs: 3% at least one 
dose (2009)  
  Public 
 
September 2008 
 
School-based program: 
x *LUOV*UDGH§-12 yrs) 
 
School-based program: 
Girls 11-12 yrs : about 50% (2009) 
 
Denmark Quadrivalent Private October 2006 
 
 
Private vaccination: 
x *LUOVDQGER\V\UV 
Private vaccination: 
x No information for total group of 
females. About 15% for those born in 
1985-1992 
 
  Public January 2009 
 
GP Childhood vaccination program: 
x Girls 12 yrs 
Children vaccination program by GPs: 
x Girls 12 yrs: 79% (2012) 
 
   October 2008 
 
GP Catch-up girls: 
x Girls 13-15 yrs (2008-2010) 
Catch-up: 
x Girls 13-15 yrs: 81% (2012) 
 
   August 2012 GP Catch-up women: 
x Women 20-27 yrs (2012-2013) 
GP Catch-up women: 
Women 20-27 yrs: 2% (2012)§ 
 
Germany Quadrivalent and 
Bivalent 
(Quadrivalent: 
90% of doses) 
 
Public March 2007 GP/community program 
x Routine vaccination of girls 12-17 yrs 
Girls 16-18: about 40% (2009) 
New Zealand Quadrivalent Public September 2008 School-based/GP/community program: 
x Girls 11-12 yrs; 
 
School-based/GP/community catch-up: 
x Girls 13-20 yrs (2008-2010) 
School-based/GP/community program: 
x Girls 11-12 yrs: around 55% (2012) 
(57% in Auckland) 
 
School-based/GP/community catch-up: 
Girls 13-20 yrs (2008-2010): 50% (2012) 
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Country Vaccine used Financing Availability of vaccine / 
Program start 
Program description* 3 doses Vaccination coverage (year)† 
Sweden Quadrivalent Partially 
subsidized 
 
October 2006 (Opportunistic 
vaccination) 
 
Opportunistic vaccination: 
x Girls 13-20 
25% at least one dose (2011) Leval 2013 
 
 
  Public 2012 School-based program: 
x Girls 11-12 yrs; 
 
School-based catch-up: 
Girls 13-18 yrs 
 
NA 
 
 
NA 
UK - England Bivalent, switch 
to Quadrivalent in 
September 2012 
Public September 2008 School-based program: 
x Girls 12-13 yrs 
 
School-based/GP catch-up: 
x Girls 14-17 yrs 
 
School-based program: 
x Girls 12-13 yrs: 84% (2011) 
 
Catch-up: 
x Girls 14-17 yrs: 56% (range from 39 to 
76%) (2011) 
 
 
UK- Scotland Bivalent, switch 
to Quadrivalent in 
September 2012 
Public September 2008 School-based program: 
x Girls 12-13 yrs 
 
School-based/GP catch-up: 
x Girls 14-17 yrs 
 
School-based program: 
x Girls 12-13 yrs: 90% (2011) 
 
Catch-up ( in and out of school): 
x Girls 13-17 yrs: 88% (33% among 
school leavers) (2011)  
 
US Quadrivalent and 
Bivalent (mostly 
Quadrivalent) 
Mix of public and 
private 
June 2006 Primary care providers vaccination: 
x Girls/women 11-12 yrs routine and 13-26 
yrs, if not previously vaccinated  
x Boys/men 11-12 yrs routine and 13-21 yrs 
if not previously vaccinated since October 
2011  
x MSM 22-26 yrs or immunocompromised 
since October 2011 
Routine and catch-up vaccination: 
x Girls 13-17 yrs: 33% (2012) 
x Women 19-26 yrs: 21% at least one 
dose (2010) 
 
 
*
 The predominant delivery method is stated where mixed methods were allowed 
†
 3-dose coverage reported, but if unavailable, coverage for at least one dose is indicated 
‡
 Possible underreporting of HPV vaccination coverage for women 20-26 years old as reported in Brotherton et al. Vaccine 2014 
§
 Few women have received 3 doses of the vaccine at this time since the catch-up program was not initiated before 2012 (37-50% had received the first HPV vaccine, 
and 28-39% had received the second) 
Data sources for vaccination coverage and program descriptions:  
Australia  
1. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national 
surveillance data. BMJ 2013; 346: f2032. 
2. Australian Government Department of Health. Information about the national Human papillomavirus (HPV) Vaccination Program funded under the Immunise 
Australia Program. http://www.health.gov.au/internet/immunise/publishing.nsf/content/immunise-hpv/ (accessed April 2014). 
3. Personal communication with Julia Brotherton 
4. National HPV Vaccination Program Register. HPV vaccination coverage by dose number (Australia) for females by age group in mid 2012. 
http://www.hpvregister.org.au/research/coverage-data/coverage-by-dose-2012 (accessed April 2014). 
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5. Brotherton JM, Liu B, Donovan B, Kaldor JM, Saville M. Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than 
previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine 2014; 32(5): 592-7. 
Canada 
1. Kliewer E, Mahmud S, Demers A, Lambert P, Musto G. Human papillomavirus vaccination and anogenital warts in Manitoba. Winnipeg: CancerCare 
Manitoba, 20pp, 2012. 
2. Kliewer E, Demers A, Lambert P. Uptake of the human papillomavirus vaccine in Manitoba August 2006-December 2009. Winnipeg: CancerCare Manitoba, 
43pp, 2012. 
Denmark 
1. Widgren K, Simonsen J, Valentier-Branth P, Molbak K. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination 
programme in Denmark. Vaccine 2011; 29: 9663-7. 
2. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Andersen KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after 
implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013; 40(2): 130-5. 
3. Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up 
of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis 2013; 57(7): 929-34. 
4. Statens Serum Institut. HPV vaccination-Coverage 2012. http://www.ssi.dk/English/News/EPI-NEWS/2013/No%2020%20-%202013.aspx (accessed April 
2014).  
5. Personnal communication  with Louise Baandrup 
Germany 
1. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human 
papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis 2013; 40(1): 28-31. 
New Zealand 
1. Ministry of Health. History of the HPV immunisation programme.  http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-
immunisation-programme/history-hpv-immunisation-programme (accessed April 2014). 
2. Oliphant J, Perkins N. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. The New Zealand 
medical journal 2011; 124(1339): 51-8. 
Sweden 
1. Leval A, Herweijer E, Arnheim-Dahlstrom L, et al. Incidence of genital warts in sweden before and after quadrivalent human papillomavirus vaccine 
availability. J Infect Dis 2012; 206(6): 860-6. 
UK (England) 
1. Mesher D, Soldan K, Howell-Jones R, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV 
immunisation in England. Vaccine 2013; 32(1): 26-32. 
2. Department of Health. Annual HPV vaccine coverage in England201/2011. 
http://media.dh.gov.uk/network/211/files/2012/03/120319_HPV_UptakeReport2010-11-revised_acc.pdf (accessed April 2014). 
UK (Scotland) 
1. Kavanagh K, Pollock KG, Potts A, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 
and closely related HPV types. Br J Cancer 2014; 110(11): 2804-11. 
2. Information Services Division. HPV immunisation uptake rates by mid-August 2012, for girls in the catch-up cohort. https://isdscotland.scot.nhs.uk/Health-
Topics/Child-Health/Publications/2012-09-25/HPV_Catch-up_Programme.xls (accessed June 2014).  
US 
1. Centers for Disease Control and Prevention. Adult Vaccination Coverage — United States, 2010. MMWR 2012;61:66- 72;  
2. Centers for Disease Control and Prevention. Human Papillomavirus Vaccination Coverage Among Adolescent Girls, 2007–2012, and Postlicensure Vaccine 
Safety Monitoring, 2006–2013 — United States. MMWR 2013;62:591-595. 
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Table S2. Methodological quality and risk of bias in studies examining changes in HPV infection between the pre- and post-vaccination periods. 
Authors Cummings 2012 Kahn 2012 Tabrizi 2012 Markowitz 2013 Mesher 2013 Sonnenberg 2013 Kavanagh 2014 
Study design Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis 
Country United States United States Australia United States England Britain Scotland 
Funding National Institutes of Health National Institutes of Health Australian National Health and 
Medical Research Council, and Anti- 
Cancer Council for Victoria 
Centers for Disease Control and 
Prevention 
Public Health England UK Medical Research Council, 
Wellcome Trust, Economic and 
Social Research Council and the 
Department of Health 
Scottish government, Chief 
Scientist Office 
Risk of selection bias        
Subjects included in the study Clinic-based: Women attending 1 of 3 
urban primary care clinics in 
Indianapolis 
Clinic-based: Young women attending 
2 primary care clinics in Cincinnati 
who had had sexual contact. Great 
proportion of minority and low-
income women 
Clinic-based: Women recruited from 
participating family planning clinics 
for Pap screening in Sydney, 
Melbourne, and Perth 
Population-based: Participants in 
NHANES which is designed to be 
nationally representative of the 
civilian, non-institutionalized US 
population 
Clinic-based: Women undergoing 
chlamydia screening at community 
sexual health services, general 
practice and youth clinics in 7 regions 
around England 
 
Population-based: Participants 
in NATSAL which is designed 
to be nationally representative 
of the British population 
Population based: Women 
attending their cervical screening 
appointment across Scotland 
Potential for selection bias: Changes in the 
study population characteristics between the 
pre- and post-vaccination periods 
 
Low 
Unlikely changes in the clientele of 
primary care clinics between the pre- 
and post-vaccination periods 
Low 
Unlikely changes in the clientele of 
primary care clinics between the pre- 
and post-vaccination periods 
Low 
Unlikely changes in the clientele of 
family planning clinics between the 
pre- and post-vaccination periods 
Low 
Unlikely changes in the NHANES 
participants between the pre- and 
post-vaccination periods 
Medium 
Documented changes in the clientele 
receiving chlamydia testing between 
the pre- and post-vaccination periods 
Medium 
Possible changes in the 
NATSAL participants between 
the pre- and post-vaccination 
periods (> 10 yrs between the 2 
periods). Both surveys are 
weighted to Census data from 
the time. 
Low 
No documented changes in 
screening rates of women aged 20-
24 years old between the pre- and 
post-vaccination periods 
Risk of information bias        
HPV testing PCR Roche Linear Array test which 
detects 37 different HPV types 
PCR Roche Linear Array test which 
detects 37 different HPV types 
Amplicor HPV test kit (Roche 
Molecular system) (13 HPV types) 
and PGMY09-PGMY11 PCR-ELISA 
Roche Linear Array HPV  
Genotyping test 
 
PCR Roche Linear Array test which 
detects 37 different HPV types 
2008: Hybrid Capture 2 and Roche 
Linear Array 
2010-2012: HPV+ In-house multiplex 
PCR and Luminex-based genotyping 
test (13 HPV types) 
In-house Luminex-based 
genotyping assay (20 HPV 
types) in urine samples 
Multimetrix HPV Assay which 
detects 18 high-risk types 
Performance of the HPV test used Unreported Unreported Unreported Unreported Unreported Unreported Unreported 
Outcome used in publication Odds ratios of HPV prevalence 
(crude) 
HPV prevalence difference (adjusted) Odds ratios of HPV prevalence 
(adjusted) 
HPV prevalence ratio 
(crude) 
Odds ratios of HPV prevalence 
(adjusted) 
Odds ratios of HPV prevalence 
(adjusted) 
HPV prevalence over time 
 
Potential for information bias: 
Errors in the identification of HPV+ during the 
pre and post-vaccination period 
 
Medium 
Potential for masking by HPV16/18, 
particularly in the pre-vaccine period 
 
Medium 
Potential for masking by HPV16/18, 
particularly in the pre-vaccine period 
 
Medium 
Potential for masking by HPV16/18, 
particularly in the pre-vaccine period 
 
Medium 
Potential for masking by HPV16/18, 
particularly in the pre-vaccine period 
 
Medium/High 
Potential for masking by HPV16/18, 
particularly in the pre-vaccine period; 
different tests used in the pre- and 
post-vaccination periods Which may 
have contributed to higher prevalence 
of non-vaccine types in the post-
vaccination period 
High 
Potential for masking by 
HPV16/18, particularly in the 
pre-vaccine period; Urine is a 
suboptimum specimen for the 
detection of HPV; Differences 
in methods of sample collection, 
preparation and storage between 
the pre- and post-vaccination 
periods  
Medium 
Potential for masking by 
HPV16/18, particularly in the pre-
vaccine period 
 
Risk of confounding        
Potential confounders considered Analysis matched on age at 
enrollment, clinic site and reported 
sexual activity (yes, never) at time of 
enrollment 
Analysis adjusted for demographic 
characteristics (race, health insurance 
plan…), gynecologic history (number 
of times pregnant, history of 
Chlamydia, AGW), behaviors (age at 
first sexual intercourse, number male 
sexual partners, condom use, 
smoking…) using propensity scores 
 
Analysis adjusted for age, 
contraceptive use, region, 
socioeconomic group and smoking 
status (these variables differed 
significantly between the 3 groups of 
women) 
Analysis adjusted for race/ethnicity, 
lifetime number of sex partners for 
girls aged 14-19 years old. No 
adjustment for the other age groups, 
but all analysis weighted to represent 
the U.S population 
Analysis adjusted for sexual history, 
age, venue type, ethnicity and 
chlamydia positivity 
No adjustment in the 
comparison of HPV prevalence 
between the pre- and post-
vaccination periods, but all 
analysis weighted to represent 
the British population 
No adjustment in the analysis of 
changes of HPV prevalence over 
time 
Potential for confounding: 
Changes in HPV infection between the pre and 
post-vaccination periods could be 
diluted/exacerbated by other variables 
Medium 
Few risk factors considered and 
residual confounding by other factors 
associated with HPV vaccination and 
infection is possible (e.g., changes in 
sexual activity) 
Low/Medium 
Several risk factors were considered. 
However, residual confounding by 
other factors associated with HPV 
vaccination and infection may still be 
present  
Medium 
Few sexual behavior factors 
considered and residual confounding 
by other factors associated with HPV 
vaccination and infection is possible  
(e.g., changes in sexual activity) 
Low/Medium 
Few factors considered for girls aged 
14-19 years old, but weighted analysis 
Medium 
Several risk factors were considered. 
However, residual confounding by 
other factors associated with HPV 
vaccination and infection can still be 
present  (e.g., changes in sexual 
activity)  
 
Medium/High 
No adjusted analysis of changes 
in HPV prevalence over time 
and likely changes over a 10-
year period in factors associated 
with HPV vaccination and 
infection (e.g., changes in sexual 
activity documented when 
comparing NATSAL-2 and -3 1) 
 
 
Medium 
No adjusted analysis of changes in 
HPV prevalence over time. 
Confounding by factors associated 
with HPV vaccination and infection 
may be present (e.g., changes in 
sexual activity) 
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Authors Cummings 2012 Kahn 2012 Tabrizi 2012 Markowitz 2013 Mesher 2013 Sonnenberg 2013 Kavanagh 2014 
Study design Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis Time-trend analysis 
Country United States United States Australia United States England Britain Scotland 
External validity        
External validity: 
Results can be generalized to the population at 
the country/region level 
 
Medium 
Young women attending to urban 
primary care clinics may not 
represent the overall population (e.g., 
different vaccination coverage)   
 
Low/Medium 
Women attending to the 2 primary 
care clinics may not be representative 
of the overall population (e.g., 
different vaccination coverage). 
Minorities and women from low 
socio-economic status are 
overrepresented 
Medium 
Young women attending family 
planning clinics may not represent the 
overall population (e.g., different 
vaccination coverage)   
 
Medium/High 
The survey was designed to be 
representative of the general 
population but non-participants could 
still be different than participants with 
respect to variables not considered in 
the sampling design. 
Medium 
Chlamydia screening recommended 
for all sexually-active young women 
and uptake was 40% in 2011. 
However, women undergoing 
chlamydia screening may not be 
representative of the overall 
population (e.g., different vaccination 
coverage)   
Medium/High 
The survey was designed to be 
representative of the general 
population. However, 
participants and those providing 
urine samples might not be fully 
representative of the general 
population, despite efforts to 
adjust for known biases and the 
use of additional weights for 
urine selection and urine non-
response. 
Medium 
Women participating in screening 
may not represent to overall 
population (e.g., different 
vaccination coverage)   
 
References:  
1. Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, Macdowall W, Lewis R, Field N, Datta J, Copas AJ, Phelps A, Wellings K, Johnson AM. Changes in sexual attitudes and lifestyles in Britain through 
the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013; 382:1781-94 
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Table S3. Methodological quality and risk of bias in studies examining changes in anogenital warts between the pre- and post-vaccination periods. 
Authors Oliphant 2011 Bauer 2012 Kliewer 2012 Leval 2012 Ali 2013 Baandrup 2013 Howell-Jones 2013 Flagg 2013 Mikolajczyk 2013 Nsouli-Maktabi 2013 Sandø 2013 
Study design Time-trends  Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends 
Country New Zealand United States Canada  Sweden Australia Denmark England United States Germany United States Denmark 
Funding No funding required CDC, California 
Department of Public 
Health 
Department of Health of 
Manitoba 
National Research School in 
Health Care Sciences, 
Strategic Research Program 
(Karolinska Institutet), 
Erasmus Programme  
CSL Biotherapies Aragon Foundation, Aase 
and Ejnar Danielsen 
Foundation, Mermaid II 
Project 
Public Health England Centers for Disease 
Control and Prevention 
Sanofi-Pasteur MSD Not mentioned Not mentioned 
Risk of selection bias           
Subjects included in 
the study 
Clinic-based: 
New clients of 1 
sexual health service 
in Auckland 
Health 
provider/insurance-
based: Clients of the 
California Family 
Planning access care & 
treatment (FPACT) 
program  
 
Population-based: 
Manitoba population from 
the population registry  
Population-based: Sweden 
population from Statistics 
Sweden 
 
Clinic-based: 
New clients of 8 sexual 
health services across 
Australia (Australian born) 
Population-based:  
Denmark population 
from Statistics Denmark 
Health provider/ based : 
Women diagnosed at 
Genitourinary medicines 
(GUM) and England 
population from national 
statistics as denominator;  
 
Health provider/insurance-
based : Enrollees in 
approximately 100 private 
health insurance plans 
across US 
Health 
provider/insurance-based 
: Enrollees in 1 large 
health insurance 
company across 
Germany 
Health provider/insurance-
based : All individuals who 
served in the US Armed 
Forces 
Population-based:  
Denmark population 
from Statistics 
Denmark 
Potential for of 
selection bias: 
Changes in the study 
population 
characteristics 
between the pre- and 
post-vaccination 
periods 
 
Medium/High 
Possible changes in 
the clientele of the 
sexual health service 
as reflected by an 
increasing annual 
number of clients in 
the post-vaccination 
period 
Low 
Unlikely change in the 
FPACT (family planning 
program for low-income 
individuals) clientele 
between the pre- and 
post-vaccination periods 
Low 
Entire population of 
Manitoba 
Low 
Entire population of Sweden 
 
Medium/High 
Possible changes in the 
clientele of the sexual health 
services in the pre- and post-
vaccination periods as 
reflected by increasing 
annual number of clients and 
% of clients with chlamydia 
after 2006 
Low 
Entire population of 
Denmark 
Low/Medium 
Possible changes in GUM 
services clientele in the 
pre- and post-vaccination 
periods  
Low 
Unlikely change in 
enrollees of insurance 
plans between the pre and 
post-vaccination periods. 
No decrease in Pap test or 
pelvic examination 
(opportunities to diagnose 
AGW) over time 
Low 
Unlikely change in 
enrollees of insurance 
plans between the pre- 
and post-vaccination 
periods 
 
Low 
Unlikely change in the 
Armed Forces population 
between the pre- and post-
vaccination periods 
Low 
Entire population of 
Denmark 
Risk of information bias           
Data source Medical records 
(available in the sexual 
health clinic database) 
FPACT database 
(clinical encounter 
claims data) 
Manitoba medical claims and 
hospital discharges 
National patient register, 
Prescribed drug register 
 
Medical records National patient register  Genitourinary Medicine 
Clinic Activity Dataset 
(GUMCAD) (diagnoses at 
GUM clinics nationally 
 
Truven Health Analytics 
MarketScan Commercial 
Claims and Encounters 
Database 
German Pharmaco-
epidemiological research 
database 
Defense Medical 
Surveillance System 
National patient 
register, Medical 
Products Statistics 
Register 
Anogenital wart case 
definition 
Clinical diagnosis ICD-9 codes 078.10, 
078.11 OR prescription 
of Imiquimod or 
Podophyllotoxin 
Treatments (1 of 14 tariff 
codes for AGW treatments) 
OR hospitalization for AGW 
with ICD-9 code 078.11 OR 
078.1, 078.10, 078.19 and 
related procedure OR ICD-10 
A630 OR B07 and related 
procedure) 
ICD-10 code A63 OR  
prescription of Imiquimod or 
Podophyllotoxin 
Clinical diagnosis ICD-10 code A63.0 Clinical diagnosis  1) ICD-9 codes 078.11 OR 
2) ICD-9 code 078.1, 
078.10, 078.19 and  
therapeutic procedure or 
diagnosis of benign 
anogenital neoplasm OR 3) 
SUHVFULSWLRQIRU$*:
treatment and therapeutic 
procedure or diagnosis of 
benign anogenital 
neoplasm 
 
ICD-10 code A63.0 ICD-9 code 078.1  ICD-10 code A63.0, 
OR prescription of 
Podophyllotoxin 
Outcome used Annual proportion of 
new clients diagnosed 
with AGW  
Annual proportion of 
FPACT clients 
diagnosed with AGW 
 
Annual incidence rate of 
diagnosed AGW in the 
population 
Annual incidence rate of 
diagnosed AGW in the 
population 
Annual proportion of new 
clients with diagnosed 
AGW  
Annual incidence rate of 
diagnosed AGW in the 
population 
Annual incidence rate of 
GUM-diagnosed AGW in 
the population 
Annual proportion of 
insured individuals with 
diagnosed AGW 
Annual incidence rate of 
diagnosed AGW among 
insured individuals 
Annual incidence rate of 
diagnosed AGW among 
US Forces members 
Annual proportion of 
the population with 
diagnosed AGW 
Numerator Number of newly 
diagnosed AGW cases 
between Jan 2007 – 
June 2010 
Number of first ever 
cases diagnosed after 
2007 (cases prior to 2007 
excluded) per year 
Number of newly diagnosed 
AGW case each year  
(washout period of 12 
months) 
Number of newly diagnosed 
AGW cases each year, 
(washout period of 6 months) 
Number of newly 
diagnosed AGW cases per 
year 
Number of newly diagnosed 
AGW cases each year 
(washout period of 12 
months) 
Number of first diagnosed 
AGW cases since 2006, 
each year 
Number of patients  with 
AGW diagnosis each year 
Number of newly 
diagnosed case each 
year, (washout period of 
12 months) 
Number of first ever 
diagnosed AGW case 
 
Number of AGW 
cases each year 
40 
 
Authors Oliphant 2011 Bauer 2012 Kliewer 2012 Leval 2012 Ali 2013 Baandrup 2013 Howell-Jones 2013 Flagg 2013 Mikolajczyk 2013 Nsouli-Maktabi 2013 Sandø 2013 
Study design Time-trends  Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends Time-trends 
Country New Zealand United States Canada  Sweden Australia Denmark England United States Germany United States Denmark 
Denominator Total number of new 
patients per year 
All clients registered in 
the FPACT each year 
Annual population estimates Annual population estimates 
 
Total number of new 
patients per year 
Annual population 
estimates  
Annual population 
estimates 
 
Total number of clients 
enrolled in in health 
insurance plans each year 
 
Total number of clients 
of 1 large insurance 
company each year 
Total number of  
individuals who served in 
the US Forces each year 
Annual population 
estimates 
Potential for 
information bias: 
Errors in the 
identification of 
diagnosed AGW cases 
during the pre and 
post-vaccination 
period 
 
Low 
AGW are directly 
diagnosed by 
physicians 
Medium 
Sensitivity/specif-icity of 
algorithm to correctly 
identify diagnosed AGW 
not specified, unlikely to 
change over time unless 
awareness is associated 
with likelihood of 
including code 
Medium 
Sensitivity/speci-ficity of 
algorithm to correctly 
identify diagnosed AGW not 
specified, unlikely to change 
over time unless awareness is 
associated with likelihood of 
including code 
Medium 
Sensitivity/specifi-city of 
algorithm to correctly 
identify diagnosed AGW not 
specified, unlikely to change 
over time unless awareness is 
associated with likelihood of 
including code 
Low 
AGW are directly 
diagnosed by physicians 
Medium 
Sensitivity/speci-ficity of 
algorithm to correctly 
identify diagnosed AGW 
not specified and AGW 
treated by GP not included, 
unlikely to change over 
time unless awareness is 
associated with likelihood 
of including code 
Low 
AGW are directly 
diagnosed by physicians in 
GUM clinics,  
Medium 
Sensitivity/speci-ficity of 
algorithm to correctly 
identify diagnosed AGW 
not specified, unlikely to 
change over time unless 
awareness is associated 
with likelihood of 
including code 
Medium 
Sensitivity/speci-ficity of 
algorithm to correctly 
identify diagnosed AGW 
not specified, unlikely to 
change over time unless 
awareness is associated 
with likelihood of 
including code 
Medium 
Sensitivity/speci-ficity of 
algorithm to correctly 
identify diagnosed AGW 
not specified, unlikely to 
change over time unless 
awareness is associated 
with likelihood of 
including code 
Medium 
Sensitivity/specificity 
of algorithm to 
correctly identify 
diagnosed AGW not 
specified, unlikely to 
change over time 
unless awareness is 
associated with 
likelihood of 
including code 
Risk of confounding           
Potential confounders 
considered 
Analysis stratified by 
age and gender  
 
Analysis stratified by 
age and gender 
Analysis stratified by age and 
gender 
Analysis stratified by age and 
gender 
Analysis stratified by age, 
gender, sexual orientation 
and residential status 
 
Analysis stratified by age 
and gender 
Analysis stratified by age 
and gender, and adjusted 
for chlamydia diagnoses 
and area  
 
Analysis stratified by age, 
gender, region, and 
insurance plan type  
Analysis stratified by 
age and gender 
Analysis stratified by age 
and gender 
Analysis stratified by 
age and gender 
Potential for 
confounding: 
Changes in diagnosed 
AGW between pre and 
post-vaccination 
periods could be 
diluted/exacerba-ted 
by other variables  
Medium 
Other factors could 
potentially cause 
changes in AGW 
frequency over time 
(e.g., changes in 
sexual activity) 
 
 
Medium 
Other factors could 
potentially cause 
changes in AGW 
frequency over time 
(e.g., changes in sexual 
activity) 
 
Medium 
Other factors could 
potentially cause changes in 
AGW frequency over time 
(e.g., changes in sexual 
activity, health seeking 
behaviour) 
Medium 
Other factors could 
potentially cause changes in 
AGW frequency over time 
(e.g., changes in sexual 
activity); data suggesting 
increasing sexual activity 
over time in Sweden 
High 
Other factors could 
potentially cause changes 
in AGW frequency over 
time (e.g., changes in 
sexual activity, health 
seeking behaviour); data 
suggest increasing 
proportion of clients with 
chlamydia after 2007 
Medium 
Other factors could 
potentially cause changes 
in AGW frequency over 
time (e.g., changes in 
sexual activity, health 
seeking behaviour)  
Medium 
Other factors could 
potentially cause changes 
in AGW frequency over 
time (e.g., changes in 
sexual activity, health 
seeking behaviour)  
Medium 
Other factors could 
potentially cause changes 
in AGW frequency over 
time (e.g., changes in 
sexual activity, health 
seeking behaviour) 
Medium 
Other factors could 
potentially cause 
changes in AGW 
frequency over time 
(e.g., changes in sexual 
activity, health seeking 
behaviour) 
Medium 
Other factors could 
potentially cause changes 
in AGW frequency over 
time (e.g., changes in 
sexual activity, health 
seeking behaviour); data 
suggesting increases in 
diagnosis of all STIs 
Medium 
Other factors could 
potentially cause 
changes in AGW 
frequency over time 
(e.g., changes in 
sexual activity, health 
seeking behaviour) 
External validity            
External validity: 
Results can be 
generalized to the 
population at the 
country/region level 
 
Medium 
Clients of 1 sexual 
health clinic may not 
represent the overall 
population (e.g., 
different vaccination 
coverage)   
Medium 
FPACT is a program for 
low-income individuals 
and 87% of participants 
are females. Results 
could be different for 
medium/high-income 
individuals (e.g., 
different vaccination 
coverage)  
High 
Entire population 
High 
Entire population 
Medium 
Clients of 8 sexual health 
clinics possibly 
representative of sexual 
health clinic clients in 
Australia, may not 
represent the overall 
population (e.g., different 
vaccination coverage) 
Medium/High 
Entire population Contains 
all cases of AGW admitted 
to hospital or in outpatient 
clinics  
Medium/High 
About 95% of AGW 
diagnoses are made in 
GUM clinics (~85% 
sample of national data 
used)  
Medium/High 
The Truven Health 
Analytics contains data 
from 100 health insurance 
plan throughout the US 
(n=13 million in 2010). 
Results could be different 
for uninsured individuals  
Medium/High 
The insurance plan 
includes > 6million 
individuals, 8% of the 
German population and 
is demographically 
representative. Results 
could be different in 
uninsured individuals 
Medium/High 
All members of the Armed 
Forces are included, but 
results could be different 
for individuals not in the 
Armed Forces  
High 
Entire population 
CDC: Centers for Disease Control and Prevention 
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Table S4. Methodological quality and risk of bias in studies examining changes in high-grade lesions between the pre- and post-vaccination periods. 
Authors Brotherton 2011/AIHW 2013 Niccolai 2013 
Study design Time-trend analysis Time-trend analysis 
Country Australia United States 
Funding none Centers for Disease Control and Prevention 
Risk of selection bias   
Subjects included in analysis  Population-based: Women included in the Victorian Cervical Cytology 
Registry 
 
Population-based: Statewide surveillance registry in Connecticut 
Potential for selection bias: Changes in the study 
population characteristics between the pre- and post-
vaccination periods 
Medium 
Possible changes in participants to cervical cancer screening between the 
pre- and post-vaccination periods 
Medium 
Possible changes in participants to cervical cancer screening between the 
pre- and post-vaccination periods 
Risk of information bias   
Diagnosis of cervical lesions The registry receives data from almost all cytology and cervical 
histopathology taken in Australia 
The surveillance system receives data from all 34 pathology laboratories 
in Connecticut 
Outcome used Annual incidence of high grade lesions Annual incidence of high grade lesions 
Potential for information bias: 
Errors in the identification of pre-cancerous cervical 
lesions during the pre and post-vaccination period 
Medium 
Sensitivity/specificity may change after vaccination, but unlikely to change 
during the first years of the vaccination program. 
Medium 
Sensitivity/specificity may change after vaccination, but unlikely to 
change during the first years of the vaccination program. 
Risk of confounding   
Potential confounders considered Analysis stratified by age 
 
Analysis stratified by age, area-based measures of ethnicity and race, and 
county type (urban-rural) 
 
Potential for confounding: 
Changes in precancerous between pre and post-
vaccination periods could be diluted/exacerbated by 
other variables  
Medium/High 
Other factors could potentially cause changes in the incidence of 
precancerous cervical lesions (e.g., changes in screening guidelines, sexual 
activity). Changes in screening guidelines documented in 20061. 
Medium/High 
Other factors could potentially cause changes in the incidence of 
precancerous cervical lesions (e.g., changes in screening guidelines, 
sexual activity). Changes in screening guidelines and in screening among 
women documented in the US2. 
External validity   
Results can be generalized to the population at the 
country/region level 
Medium/High 
Women participating in screening may not be representative of the overall 
population (e.g., different vaccination coverage)   
Medium/High 
Women participating in screening may not be representative of the 
overall population (e.g., different vaccination coverage)   
 AIHW: Australian Institute of Health and Welfare 
 
References:  
1. NHMRC. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities, 2005. http://www.nhmrc.gov.au/publications/ 
synopses/wh39syn.htm (accessed Dec 2010). 
2. MMWR Jan 2013. Cervical cancer screening among women aged 18-30 years – United States, 2000-2010 
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Table S5. Pre and post-vaccination years considered in the meta-analysis. 
Study Country HPV vaccination 
introduction 
Pre-vaccination years considered in the meta-
analysis 
Post-vaccination years ۅ௘ 
   1 2 3 4 5 § 
HPV infection *         
Cummings 2012  U.S. 2006 1995-2005    2010  
Kahn 2012 ‡   U.S. 2006 2006-2007   2009 2010  
Tabrizi 2012 Australia 2007 2005-2007   2010 2011  
Markowitz 2013 U.S.  2006 2003-2006 2007 2008 2009 2010  
Mesher 2013 England 2008 2008  2010 2011 2012  
Sonnenberg 2013 Britain 2008 1999-2001  2010 2011 2012  
Kavanagh 2014 ‡ Scotland 2008 2009-2010   2011 2012  
AGW consultations †         
Oliphant 2011 New Zealand 2008 2007-2008 2009 2010    
Bauer 2012 ‡  U.S. 2006 2007  2008 2009 2010  
Kliewer 2012 Canada 2008 2006-2008 2009     
Leval 2012 Sweden 2006 2006 2007 2008 2009 2010  
Ali 2013 Australia 2007 2005-2007 2008 2009 2010 2011 2012 
Baandrup 2013 Denmark 2009 2007-2009 2010 2011    
Howell-Jones 2013 England 2008 2006-2008 2009 2010 2011   
Flagg 2013 U.S. 2006 2004-2006 2007 2008 2009 2010  
Mikolajczyk 2013 Germany 2007 2005-2007 2008     
Nsouli-Maktabi 2013 U.S. 2006 2004-2006 2007 2008 2009 2010 2011 
Sandø 2013 Denmark 2009 2007-2009 2010 2011    
High–grade precancerous lesions        
Brotherton 2011/AIHW 2013 Australia 2007 2005-2007 2008 2009 2010 2011  
Niccolai 2013 ‡ U.S. 2006 2008   2009 2010 2011 
AIHW: Australian Institute of Health and Welfare 
*  For HPV infection, pre- and post-vaccination years were determined in original studies. The impact measure presented in original studies compared the combined post-
vaccination years to the combined pre-vaccination. The only exception is the study by Kavanagh et al., in which yearly prevalence was presented separately for 2009, 
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2010, 2011, and 2012. We considered 2009 and 2010 as pre-vaccination years since the vaccination coverage was very low and 2011 and 2012 as post-vaccination 
years. 
† For anogenital warts, pre-vaccination years (up to 3 according to the data available) were determined for the purpose of the meta-analysis. We included the calendar 
year of HPV vaccination introduction in the pre-vaccination period because year-end vaccination coverage with more than one dose was very low. All subsequent 
years were considered as post-vaccination years. 
‡
  Studies where the pre-vaccination years considered in the analysis included 1 or 2 years after the introduction of HPV vaccination, but during which the vaccination 
coverage was considered low (i.e. < 15%).  
§  Since only two studies examined AGW during the fifth year after the introduction of HPV vaccination (1 with a high coverage and 1 with a low coverage), we 
restricted the analysis to four years. Similarly, for cervical lesions, the analysis was restricted to the first four years. 
ۅ௘
 Blanks in the post-vaccination years indicate that the study did not evaluate the outcome in this year  
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Table S6. Results of the sensitivity analysis using the results of Sandø et al instead of Baandrup et al. 
 Baandrup et al.  Sandø et al. 
 Females  Males  Females  Males 
 < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs 
Results presented in Figure 3           
Study estimate  
  
0·54 
(0·49;0·60) 
0·79 
(0·74;0·83) 
 0·80 
(0·63;1·01) 
0·82 
(0·77;0·87) 
 0·48 
(0·46;0·51) 
0·97 
(0·95;0·99) 
 0·67 
(0·63;0·72) 
1·09 
(1·07;1·12) 
Summary for the quadrivalent vaccine 
 
Heterogeneity for the quadrivalent 
summary estimate  
0·69 
(0·60;0·79) 
 
I2 = 97% 
p<0·00001 
0·89 
(0·79;1·02) 
 
I2 = 99% 
p<0·00001 
 0·95 
(0·84;1·08) 
 
I2 = 93% 
p<0·00001 
1·01 
(0·88;1·17) 
 
I2 = 99% 
p<0·00001 
 0·67 
(0·56;0·80) 
 
I2 = 99% 
p<0·00001 
0·92 
(0·82;1·03) 
 
I2 = 99% 
p<0·00001 
 0·91 
(0·78;1·07) 
 
I2 = 96% 
p<0·00001 
1·05 
(0·93;1·18) 
 
I2 = 99% 
p<0·00001 
Results presented in Figure S2- Appendix           
Vaccine 
 Quadrivalent 
  
             Bivalent 
 
0·69 
(0·60;0·79) 
0·96 
(0·94;0·97) 
 
I2 = 95% 
p<0·00001 
 
0·89 
(0·79;1·02) 
1·00 
(0·98;1·01) 
 
I2 = 62% 
p=0·10 
  
0·95 
(0·84;1·08) 
1·03 
(1·01;1·05) 
 
I2 = 26% 
P=0·25 
 
1·01 
(0·88;1·17) 
1·02 
(1·00;1·03) 
 
I2 = 0%  
p=0·96 
  
0·67 
(0·56;0·80) 
0·96 
(0·94;0·97) 
 
I2 = 93% 
p=0·0001 
 
0·92 
(0·82;1·03) 
1·00 
(0·98;1·01) 
 
I2 = 50% 
p=0·16 
  
0·91 
(0·78;1·07) 
1·03 
(1·01;1·05) 
 
I2 = 53% 
p=0·15 
 
1·05 
(0·93;1·18) 
1·02 
(1·00;1·03) 
 
I2 = 0% 
·p=0·65 
Quadrivalent vaccine            
Coverage 
 Low 
 
 High 
 
0·86 
(0·79;0·94) 
0·39 
(0·22;0·71) 
 
I2 = 85% 
p=0·01 
 
1·02 
(0·90;1·16) 
0·68 
(0·51;0·89) 
 
I2 = 86% 
p=0·008 
  
1·07 
(0·93;1·22) 
0·66 
(0·47;0·91) 
 
I2 = 86% 
p=0·007 
 
1·13 
(0·95;1·33) 
0·82 
(0·72;0·92) 
 
I2 = 90% 
p=0·002 
  
0·86 
(0·79;0·94) 
0·38 
(0·23;0·63) 
 
I2 =89% 
p=0·002 
 
1·02 
(0·90;1·16) 
0·73 
(0·48;1·10) 
 
I2 = 59% 
p=0·12 
  
1·07 
(0·93;1·22) 
0·63 
(0·51;0·77) 
 
I2 = 94% 
p<0·0001 
 
1·13 
(0·95;1·33) 
0·90 
(0·68;1·20) 
 
I2 = 42% 
p=0·19 
Age 
 15-19 yrs 
  
             20-24 yrs 
  
             25-29 yrs 
  
            30-39 yrs  
 
0·69 
(0·60;0·79) 
 
 
 
0·84 
(0·75;0·94) 
0·88 
(0·75;1·02) 
1·04 
(0·92;1·18) 
 
I2 = 70% 
p=0·04 
  
0·95 
(0·84;1·08) 
 
 
 
0·96 
(0·83;1·10) 
1·04 
(0·89;1·21) 
1·06 
(0·93;1·21) 
 
I2 = 0%  
p=0·55 
  
0·67 
(0·56;0·80) 
 
 
 
0·86 
(0·77;0·95) 
0·91 
(0·80;1·04) 
1·08 
(0·96;1·20) 
 
I2 = 78% 
p=0·01 
  
0·91 
(0·78;1·07) 
 
 
 
0·97 
(0·86;1·10) 
1·08 
(0·95;1·23) 
1·11 
(0·99;1·24) 
 
I2 = 20% 
p=0·29 
Years since vaccination 
 Year 1 
 
 Year 2 
 
 
0·84 
(0·73;0·97) 
0·67 
(0·56;0·80) 
 
0·93 
(0·85;1·02) 
0·88 
(0·77;1·01) 
  
1·00 
(0·96;1·04) 
0·97 
(0·85;1·12) 
 
1·01 
(0·94;1·08) 
0·97 
(0·84;1·11) 
  
0·82 
(0·68;0·99) 
0·62 
(0·45;0·84) 
 
0·96 
(0·88;1·03) 
0·94 
(0·85;1·05) 
  
0·96 
(0·88;1·05) 
0·86 
(0·68;1·09) 
 
1·03 
(0·97;1·10) 
1·04 
(0·94;1·16) 
45 
 
 Baandrup et al.  Sandø et al. 
 Females  Males  Females  Males 
 < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs 
 Year 3 
 
 Year 4 
 
0·73 
(0·62;0·86) 
0·59 
(0·48;0·71) 
 
I2 = 68% 
p=0·02 
0·91 
(0·74;1·12) 
0·80 
(0·65;1·00) 
 
I2 = 0% 
p=0·65 
1·02 
(0·82;1·27) 
0·93 
(0·72;1·19) 
 
I2 = 0%  
p=0·92 
1·07 
(0·83;1·37) 
1·01 
(0·78;1·32) 
 
I2 = 0% 
P=0·91 
0·73 
(0·62;0·86) 
0·59 
(0·48;0·71) 
 
I2 = 56% 
P=0·08 
0·91 
(0·74;1·12) 
0·80 
(0·65;1·00) 
 
I2 = 0% 
p=0·53 
1·02 
(0·82;1·27) 
0·93 
(0·72;1·19) 
 
I2 = 0% 
p=0·75 
1·07 
(0·83;1·37) 
1·01 
(0·78;1·32) 
 
I2 = 0% 
·p=0·99 
Data source 
 Population-based 
 
 Health/Insurance-based 
 
 Clinic-based 
 
0·81 
(0·52;1·26) 
0·81 
(0·76;0·87) 
0·33 
(0·11;0·99) 
 
I2 = 23% 
p=0·27 
 
0·88 
(0·74;1·05) 
1·07 
(0·90;1·26) 
0·63 
(0·42;0·93) 
 
I2 = 69% 
p=0·04 
  
1·02 
(0·80;1·30) 
1·04 
(0·88;1·24) 
0·58 
(0·39;0·86) 
 
I2 = 73%  
p=0·03 
 
0·96 
(0·80;1·15) 
1·17 
(0·93;1·48) 
0·82 
(0·65;1·02) 
 
I2 = 58% 
P=0·09 
  
0·78 
(0·44;1·38) 
0·81 
(0·76;0·87) 
0·33 
(0·11;0·99) 
 
I2 = 24% 
p=0·27 
 
0·97 
(0·96;0·99) 
1·07 
(0·90;1·26) 
0·63 
(0·42;0·93) 
 
I2 = 65% 
p=0·06 
  
0·94 
(0·61;1·45) 
1·04 
(0·88;1·24) 
0·58 
(0·39;0·86) 
 
I2 = 72% 
p=0·03 
 
1·07 
(1·04;1·11) 
1·17 
(0·93;1·48) 
0·82 
(0·65;1·02) 
 
I2 = 67% 
p=0·05 
Results presented in Figure 4            
High coverage 
 < 20 yrs 
  Year 1 
 
  Year 2 
 
  Year 3 
 
  Year 4 
 
 
 
0·60 
(0·48;0·74) 
0·30 
(0·22;0·41) 
0·12 
(0·07;0·21) 
0·07 
(0·03;0·13) 
 
   
 
0·85 
(0·69;1·04) 
0·56 
(0·42;0·75) 
0·36 
(0·21;0·59) 
0·38 
(0·23;0·63) 
   
 
0·59 
(0·49;0·71) 
0·31 
(0·23;0·42) 
0·12 
(0·07;0·21) 
0·07 
(0·03;0·13) 
 
   
 
0·82 
(0·76;0·89) 
0·52 
(0·47;0·57) 
0·36 
(0·21;0·59) 
0·38 
(0·23;0·63) 
 
 20-24 yrs 
  Year 1 
 
  Year 2 
 
  Year 3 
 
  Year 4 
 
 
 
 
0·75 
(0·61;0·91) 
0·60 
(0·45;0·80) 
0·22 
(0·16;0·31) 
0·17 
(0·12;0·25) 
  
 
 
0·94 
(0·86;1·01) 
0·73 
(0·64;0·82) 
0·53 
(0·45;0·63) 
0·45 
(0·37;0·54) 
   
0·77 
(0·59;1·00) 
0·69 
(0·49;0·96) 
0·22 
(0·16;0·31) 
0·17 
(0·12;0·25) 
   
0·97 
(0·82;1·14) 
0·85 
(0·69;1·04) 
0·53 
(0·45;0·63) 
0·45 
(0·37;0·54) 
 25-29 yrs 
  Year 1 
 
  Year 2 
 
  Year 3 
 
  Year 4 
 
 
 
 
0·74 
(0·60;0·90) 
0·62 
(0·53;0·71) 
0·42 
(0·30;0·57) 
0·34 
(0·23;0·50) 
  
 
 
0·87 
(0·80;0·95) 
0·73 
(0·56;0·96) 
0·73 
(0·62;0·86) 
0·64 
(0·53;0·76) 
   
0·78 
(0·56;1·10) 
0·76 
(0·52;1·13) 
0·42 
(0·30;0·57) 
0·34 
(0·23;0·50) 
   
0·96 
(0·78;1·18) 
0·94 
(0·74;1·20) 
0·73 
(0·62;0·86) 
0·64 
(0·53;0·76) 
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 Baandrup et al.  Sandø et al. 
 Females  Males  Females  Males 
 < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs  < 20 yrs 20-39 yrs 
 30-39 yrs 
  Year 1 
 
  Year 2 
 
  Year 3 
 
  Year 4 
 
 
 
 
0·85 
(0·76;0·95) 
0·79 
(0·58;1·08) 
1·28 
(0·98;1·67) 
0·78 
(0·56;1·09) 
  
 
 
0·85 
(0·76;0·95) 
0·79 
(0·60;1·04) 
0·83 
(0·71;0·97) 
0·76 
(0·65;0·90) 
   
0·91 
(0·75;1·11) 
0·97 
(0·86;1·09) 
1·28 
(0·98;1·67) 
0·78 
(0·56;1·09) 
   
0·92 
(0·73;1·17) 
0·99 
(0·79;1·24) 
0·83 
(0·71;0·97) 
0·76 
(0·65;0·90) 
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Figure S1. Changes in the incidence of high-grade cervical lesions between the pre and post-vaccination period among females aged 15-39 years old. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIHW: Australian Institute of Health and Welfare 
 
